Volume 13, Number 6—June 2007
Perspective
Economic Evaluation and Catheter-related Bloodstream Infections
Kate Halton*†
and Nicholas Graves*†
and Nicholas Graves*†
Table 6
Ranks of evidence for parameters used in the decision models*
| Evidence ranking | Clinical effectiveness of intervention, n = 8 | Baseline incidence CR-BSI, n = 8 | Attributable mortality, n = 7 | Incidence localized insertion site infection, n = 5 | Cost of CR-BSI, n = 8 | Cost of intervention, n n = 8 |
|---|---|---|---|---|---|---|
| High quality | ||||||
| Rank 1 | 5 | 1 | – | – | 2 | – |
| Rank 2 | 1 | 1 | 1 | – | 1 | 7 |
| Medium quality | ||||||
| Rank 3 | – | 1 | 1 | – | 2 | – |
| Low quality | ||||||
| Rank 4 | 1 | 4 | 4 | 4 | 2 | – |
| Rank 5 | – | 1 | 1 | 1 | – | – |
| Rank 6 | – | – | – | – | – | – |
| Unclear | 1 | – | – | – | 1 | 1 |
*CR-BSI, catheter-related bloodstream infections.
Page created: July 05, 2010
Page updated: July 05, 2010
Page reviewed: July 05, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.